subjectivity, inconsistency and inter-observer variations. The limitations of IHC method 23 may be used to explain the discordance between microarray-based intrinsic subtyping 24 and IHC-based surrogate assay of breast cancer patients in clinical practice [1] [2] [3] .
25
Hundreds of genes were analyzed in initial microarray analysis of breast cancer tissues 26 to reveal four intrinsic subtypes of breast cancers, including Luminal, Erb2 (Her2 type), 27 basal-like and normal-like (intrinsic subtyping) 4, 5 . However, later microarray studies 28 suggested that a few gene modules including ER and Her2 modules may be sufficient for 29 subtyping of breast cancer patients [6] [7] [8] [9] .
While microarray analysis is limited to 30 retrospective studies only, surrogate assay was developed in clinical practice. This assay 31 was based on the IHC analysis of four protein biomarkers of Estrogen receptor (ER),
32
Progesterone receptor (PR), Ki67 and Her2 to achieve fair but unsatisfactory 33 concordance with intrinsic subtyping [1] [2] [3] 10 .
34
Based on these studies, we hypothesized that the intrinsic subtypes of breast cancer be dispensable once the protein levels of these biomarkers are measured quantitatively.
4
The IHC-based surrogate assay is obviously insufficient in this aspect by its dichotomous 40 classification of protein biomarkers [3] [4] [5] . Indeed, studies based on Selected Reaction 
63
The distribution of all four biomarkers were shown in Fig 1a- The absolute and quantitative levels of Her2, ER, PR, and Ki67 were measured with Quantitative Dot Blot (QDB) method using lysates prepared from 2X15 μm FFPE slices. The average levels of these biomarkers were expressed as mean ± SEM. The 25th and 75th percentiles were also listed for each biomarker respectively. The results were reported as the average of three independent measurements of these four biomarkers, with each measurement in triplicate. 1e-1h: The correlations between QDB and IHC results were analyzed among those samples with available IHC scores using Spearman's rank correlation analysis with p<0.0001 for all analysis. For ER, PR and Ki67, these samples were sub-grouped based on their IHC scores, and correlation of their subgroup averages with the matching IHC scores were analyzed again with Pearson's correlation analysis. The Ki67 levels of these three groups were evaluated in Fig.3a expression were all within this group.
114
When observing the 3D scatterplots of ER-Her2-Ki67 (Fig 3b) , ER-PR-Ki67 and PR-Her2- Operative Characteristic (ROC) analysis was performed with measured Her2 levels. As The spatial distribution of samples using ER, Her2 and Ki67 levels as X, Y and Z axes. Those samples with PR level <0.8 nmole/g were arbitrarily set to the color red, while those with PR level ≥0.8 nmole/g were set to the color blue. We observed that those samples with the highest Ki67 levels were exclusively red around the intersection of ER and Her2, suggesting a lack of ER, PR, and Her2 expression.
8 expected, we confirmed Her2 at 0.3 nmole/g as the optimized cutoff value to achieve the 129 best sensitivity and specificity at 84.8% and 97.6% respectively with IHC results, with 130 overall concordance rate at 93.6% with IHC analysis (Fig. 4a & 4b) . , and were used for Receiver Operative Characteristics (ROC) analysis using GraphPad Software. We were able to achieve Area Under the Curve (AUC) at 0.933±0.014, 95%CI at 0.905~0.961 (p<0.0001). Using 0.3 nmole/g as the cutoff, we achieved sensitivity at 84.8% and specificity at 97.6%. The concordant rate was at 93.6% (560 out of 598, samples with a Her2 score of 2+ were excluded from analysis) with IHC results. (b) To better illustrate the effectiveness of this cutoff (indicated by the dashed line) at separating negative samples from positive ones, samples were plotted in log scale and grouped based on their respective IHC scores. All those samples with their Her2 levels measured as 0 were arbitrarily set as 0.001 nmole/g to avoid being omitted in the log scale plot. expression vector respectively and expressed in E.coli BL21(DE3) competent cells.
247
The cells were induced with 1mM IPTG, and total bacterial lysates were extracted in 
Preparation of FFPE tissue and cell lysates

256
Two whole tissue slices (2X15m) from FFPE blocks were put into 1.5ml Eppendorf 257 tubes, and deparaffinized before they were solubilized using solubilization buffer(50mM
258
Tris-HCl, 10 mM EDTA, 1% Tween 20, 10% glycerol, pH 9.9). Cells (MCF-7& BT474 259 cells) were lysed in the lysis buffer (50mM HEPES, 137mM NaCl, 5mM EDTA, 1mM
260
MgCl2, 10mM Na2P2O7, 1%TritonX-100, 10% glycerol, pH7.6) with protease inhibitors
261
(2g/ml Leupeptin, 2g/ml Aprotinin, 1g/ml pepstatin, 2mM PMSF, 2mM NaF). The 262 supernatants were collected after centrifugation and the total amount of protein was 263 measured using BCA protein assay kit by following manufacturer's instructions. Extended Data 1. Defining the linear ranges of QDB method for measuring Her2, Estrogen receptor (ER), Progesterone receptor (PR) and Ki67 levels using validated IHC antibodies as indicated in the figure. Fig. 1a-1d : Pooled samples prepared from 2X15 μm FFPE slices obtained from 4 patients testing positive based on IHC analyses of these biomarkers were used to define the linear range of QDB method for these biomarkers respectively. Pooled samples were serially diluted and supplemented with IgG-free BSA at a final amount of 0.5 μg/unit for Her2 and Ki67, and 0.25 μg/unit for ER and PR. The chemiluminescence signals were captured with a Tecan microplate reader, and used for linear regression analysis with the matching amount of total protein lysates used in the QDB analysis. The linear range of the analysis was defined as where the coefficient of determination (R 2 ) was above 0.99. Fig. 1e-1h : Purified recombinant protein, either obtained commercially (Her2), or purified in the house (ER, PR and Ki67) were loaded at the amount indicated in the figure legends, and supplemented with IgG-free BSA to match the final loading amount for sample analysis at 0.25 μg/unit for ER and PR, and 0.5 μg/unit for Her2 and Ki67. The chemiluminescence signals were captured with a Tecan microplate reader, and used for linear regression analysis with the matching amount of protein standard used in the QDB analysis. The linear range of the analysis was defined as the region where the coefficient of determination (R 2 ) was above 0.99. Extended Data 2: Consistency of the QDB measurement of Her2 (a) and Ki67 (b) levels using two independent validated IHC antibodies respectively. (a) Total lysates prepared from 2X15 μm FFPE slices were used for QDB measurements of Her2 levels at 0.5 μ g/sample with EP3 and 4B5 antibodies respectively, as described in Materials and Methods. The correlation between Her2 levels from EP3 and 4B5 measurements were analyzed with Pearson's correlation analysis in 332 samples. P<0.0001. (b) The same lysates from (a) were also used for measurements of Ki67 levels using MIB1 and UMAB107 respectively in 332 samples. The correlation between Ki67 levels from MIB1 and UMAB107 measurements were analyzed using Pearson's correlation analysis. P<0.0001. 
